U.S. FDA approves expanded use of BioMarin's dwarfism therapy

In this article:

Oct 20 (Reuters) - The U.S. Food and Drug Administration (FDA) on Friday approved the expanded use of BioMarin Pharmaceutical's once-daily injection to treat children under the age of 5 with the most common form of short-limbed dwarfism.

(Reporting by Pratik Jain and Khushi Mandowara in Bengaluru; Editing by Shailesh Kuber)

Advertisement